{
    "ucits": true,
    "type": "ETF",
    "leverage": false,
    "derivatives": true,
    "swaps": true,
    "inverse": false,
    "replication_method": "synthetic",
    "complex_factors": "Synthetic replication via OTC swaps, exposure to US Treasury futures, counterparty and collateral risk, complex index strategy",
    "classification": "complex",
    "supporting_data": "The Amundi US Curve steepening 2-10Y UCITS ETF is a UCITS-compliant ETF that uses synthetic replication by entering into an OTC swap contract to replicate the performance of a benchmark index based on long and short positions in US Treasury Note futures (2-year and 10-year contracts). This involves derivatives integral to the investment objective, introducing counterparty risk and collateral risk, which are difficult for retail investors with basic knowledge to understand. The ETF's benchmark index strategy is complex, involving a steepening strategy of the US interest rate curve and accounting for funding costs. The ETF also invests in a diversified portfolio of international bonds, but the synthetic replication and swap usage dominate the complexity assessment. According to MiFID II Article 254 and Delegated Regulation EU 2017/565 Article 57, such use of derivatives integral to the strategy and synthetic replication generally classifies the ETF as complex. The ETF does not use significant leverage beyond UCITS limits, but the presence of embedded derivatives (swaps) and synthetic replication leads to a complex classification. The structure and risks (counterparty, collateral, derivative usage) are not straightforward for retail investors, failing the non-complex criteria. Therefore, despite being a UCITS ETF, the product is complex under MiFID II rules and requires an appropriateness assessment before sale to retail clients."
}